Back to mobile site
Get it on Google Play

BioVersys gets FDA clearance to start phase 3 trial for BV100

March 16, 2026 2:00 AM EDT Send to a Friend
BioVersys AG (SIX: BIOV) announced that the U.S. Food and Drug Administration has confirmed the company may proceed with its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login